Applications of mass spectrometry in the clinical laboratory

Colby, Jennifer M.; Thoren, Katie L.

doi:10.1016/b978-0-12-815499-1.00021-1

Cited by 3 publications

(4 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Selected ion monitoring mode was used to estimate the CEE traces with high‐quality precision and sensitivity. Atmospheric pressure chemical ionization, which is similar to electrospray ionization technique, was chosen for the CEE estimation, as it worked effectively for the estimation of small and liquid molecules with lower polarities (Colby & Thoren, 2020; Lee et al, 2015; Thomas, 2019). A drying temperature of 250°C and a vaporization temperature of 400°C were applied to de‐solvate the buffer rapidly into aerosol droplets in a stream of nitrogen gas.…”

Section: Resultsmentioning

confidence: 99%

“…Selected ion monitoring mode was used to estimate the CEE traces with high-quality precision and sensitivity. Atmospheric pressure chemical ionization, which is similar to electrospray ionization technique, was chosen for the CEE estimation, as it worked effectively for the estimation of small and liquid molecules with lower polarities (Colby & Thoren, 2020;Lee et al, 2015;Thomas, 2019). A drying tem- As shown in Table 2, various trials were carried out by changing the nebulizer gas (N 2 ) pressure, drying gas (N 2 ) flow rate, drying gas (N 2 ) temperature and vaporizer temperature, but all of the changes made, except for the nebulizer gas pressure, under ionization parameters did not have any influence on the detection and estimation of CEE.…”

Section: Selection Of Ionization Parametersmentioning

confidence: 99%

“…Consider the need for better therapy, the authors have developed a new LC–MS/MS method for the estimation of CEE in the API and formulated drug product of hydroxyzine tablets. LC–MS/MS is a widely used powerful and sophisticated analytical technique that combines the separating power of chromatography with highly sensitive and selective mass analysis capability using triple quadruple mass spectrometry (Agilent, 2007, 2010; Colby & Thoren, 2020; Lakka et al, 2021; Lee et al, 2015; Narasimha et al, 2020; Pitt, 2009; Thomas, 2019).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Development and validation of liquid chromatography–tandem mass spectrometry method for the estimation of a potential genotoxic impurity 2‐(2‐chloroethoxy)ethanol in hydroxyzine

Lakka

Kuppan

Ravinathan³

et al. 2022

Biomedical Chromatography

View full text Add to dashboard Cite

2-(2-Chloroethoxy)ethanol (CEE) belongs to the so-called cohort of concerns which were classified as highly potent mutagenic carcinogens by the World Health Organization. It is widely used in the synthesis of the essential anti-histamine drug hydroxyzine. In addition, it is used as a primary solvent in dyes, nitrocellulose, paints, inks and resins. Owing to its potential genotoxicity, an efficient liquid chromatographytandem mass spectrometry method was developed for the quantitative estimation of CEE traces in an active pharmaceutical ingredients and in tablet dosage forms of hydroxyzine-free base. The chromatographic separation was achieved on a C 18 column using a gradient elution mode with a binary solvent system (ammonium formate

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Selection Of Ionization Parametersmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Development and validation of liquid chromatography–tandem mass spectrometry method for the estimation of a potential genotoxic impurity 2‐(2‐chloroethoxy)ethanol in hydroxyzine

Lakka

Kuppan

Ravinathan³

et al. 2022

Biomedical Chromatography

View full text Add to dashboard Cite

show abstract

“…Nevertheless, there are major challenges and legal issues related to MS adoption because these assays are primarily laboratory-developed diagnostics. 7…”

Section: Discussionmentioning

confidence: 99%

Mass spectrometry in clinical laboratory: applications and future prospects

Ghonaim,

Bakr,

Alturki

et al. 2023

Int J Community Med Public Health

View full text Add to dashboard Cite

Innovations in laboratory medicine face additional challenges due to the unmet need for extremely precise methods of disease diagnosis. Developments in mass spectrometry-based disease biomarker identification are constantly expanding the field of clinical diagnosis. More mass spectrometry-based in vitro diagnostics are anticipated to move from the bench to the bedside shortly, although several are currently incorporated into standard clinical procedures. The molecular detection by mass spectrometry technique is very effective in diagnosis of the disease and therapeutic monitoring because of its extremely high sensitivity, specificity, and short turnaround time. Mass spectrometry is a potent analytical instrument that may be used to analyse a variety of materials and matrices; its use in clinical laboratory medicine applications is rising. For clinical prognostics and diagnostic purposes, mass spectrometry imaging has been widely utilized to distinguish between healthy and diseased tissues. Modern single-cell studies will benefit from its cutting-edge applications, which will offer comprehensive cellular biochemical data for mechanistic comprehension and, eventually, the development of therapeutic interventions. Within the field of laboratory medicine, the application of mass spectrometry is crucial, especially in terms of diagnostics and therapeutic drug monitoring. This review on the clinical application of mass spectrometry and its future prospects promises an insightful exploration of the evolving landscape of mass spectrometry in clinical settings, delving into its current applications and shedding light on its potential future advancements, for which a comprehensive search in the PubMed, ScienceDirect, and Web of Science databases was conducted.

show abstract

Determining the diagnostic value of the markers of congenital metabolic disorders by chromatography–mass spectrometry

Mamedov,

Zolkina,

Sukhorukov

et al. 2024

BRSMU

View full text Add to dashboard Cite

Thorough investigation of metabolome by mass spectrometry is of great importance for personalized and preventive medicine. It is only timely laboratory diagnosis involving the use of high-tech chromatographic analysis methods that can help identify the patients with disorders of amino acid and acylcarnitine metabolism. The study was aimed to determine the efficacy of conventional and additional markers of metabolic disorders of amino acids and acylcarnitines detected by chromatography–mass spectrometry for the diagnosis of congenital metabolic disorders in children, as well as to create specific panels of the most effective indicators and determine the potential diagnostic efficacy of indentification of the relationships between the levels of amino acids and acylcarnitines in pediatric patients with congenital metabolic disorders. We assessed amino acid and acylcarnitine profiles in blood spots by high-performance liquid chromatography–tandem mass spectrometry in patients aged 6 months to 16 years (48 boys and 32 girls) with suspected aminoacidopathy and organic aciduria/acidemia. The comparison group consisted of 35 children with suspected peroxisomal metabolic disorders, the control group included 40 generally healthy children of various age groups. The data obtained were used to conduct the analysis of correlations between the groups of markers. Strong correlation was revealed for the levels of metabolically most closely related compounds (r < 0.8, р < 0.001). However, a similar relationship between metabolically not closely related compounds (correlation coefficient 0.45–0.73 (р < 0.001)) was revealed for some groups of compounds. Thus, the acylcarnitine profile can be proposed as an additional potential marker to be used in cases of borderline phenylalanine levels, and the sum of normalized acylcarnitine levels (С12+С16) can be a potential secondary marker of phenylketonuria.

show abstract

Applications of mass spectrometry in the clinical laboratory

Cited by 3 publications

References 45 publications

Development and validation of liquid chromatography–tandem mass spectrometry method for the estimation of a potential genotoxic impurity 2‐(2‐chloroethoxy)ethanol in hydroxyzine

Development and validation of liquid chromatography–tandem mass spectrometry method for the estimation of a potential genotoxic impurity 2‐(2‐chloroethoxy)ethanol in hydroxyzine

Mass spectrometry in clinical laboratory: applications and future prospects

Determining the diagnostic value of the markers of congenital metabolic disorders by chromatography–mass spectrometry

Contact Info

Product

Resources

About